Evidence map›Paper›PMID 42249904›Full record

ArticleSurgery today2026

Trace element-enriched collagen peptide beverage is associated with a lower incidence of chemotherapy-induced diarrhea during DCF therapy for esophageal squamous cell carcinoma: A retrospective exploratory study.

Akira Saito, Takeshi Yamashita, Satoru Goto, Tomotake Ariyoshi, Kentaro Motegi, Masahiro Kohmoto, Koji Otsuka, Masahiko Murakami, Takeshi Aoki

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akira SaitoDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan. asaito1205@med.showa-u.ac.jp.
Takeshi YamashitaDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan.
Satoru GotoDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan.
Tomotake AriyoshiDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan.
Kentaro MotegiDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan.
Masahiro KohmotoDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan.
Koji OtsukaDigestive Diseases Center, Showa Medial University Koto Toyosu Hospital, Tokyo, Japan.
Masahiko MurakamiEsophageal Cancer Center, Showa Medical University Hospital, Tokyo, Japan.
Takeshi AokiDivision of General and Gastroenterological Surgery, Department of Surgery, Showa Medical University School of Medicine, 1-5-8, Hatanodai, Tokyo, 142-8666, Shinagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy is commonly used for esophageal squamous cell carcinoma in Japan, but it often causes chemotherapy-induced diarrhea (CID), thus impairing the quality of life. We investigated the association between a trace element-enriched collagen peptide beverage (CP10) and CID during DCF therapy.

methodsThis retrospective study included 94 patients who underwent radical esophagectomy following DCF therapy (January 2023-December 2025). During the first DCF cycle, 26 patients consumed CP10 daily (CP+ group), whereas 68 did not (CP- group). The primary endpoint was CID incidence during the first DCF cycle, assessed using the Common Terminology Criteria for Adverse Events. A multivariable logistic regression analysis was performed to adjust for any potential confounders.

resultsGrade ≥ 1, ≥2, and ≥ 3 CID occurred in 15%, 15%, and 12% of the CP+ group versus 46%, 38%, and 32% of the CP- group, respectively. CP10 use was associated with a lower incidence of CID across all severity grades. In the multivariable analysis, this association remained statistically significant for grade ≥ 1 CID (adjusted OR 0.22, 95% CI 0.05-0.74; P = 0.013). Sensitivity analyses yielded consistent estimates (adjusted OR 0.15-0.28).

conclusionCP10 use was associated with a lower incidence of CID during DCF therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBeveragesCollagenDiarrheaEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaPeptidesTrace ElementsAgedCisplatinDocetaxelEsophagectomyFemaleFluorouracilHumansIncidenceCisplatinCollagenDocetaxelFluorouracilPeptidesTrace ElementsCollagen peptideDCF therapyDiarrheaEsophagectomyTrace-element

Identifiers

PMID42249904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.